<DOC>
	<DOC>NCT02211924</DOC>
	<brief_summary>Study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 44847 in Japanese healthy volunteers</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male Subjects</brief_title>
	<detailed_description />
	<criteria>Subjects will be healthy male volunteers who meet the criteria below: Persons without clinically remarkable findings or clinically evident complications based on their concurrent illness, past medical history, physical examination, vital signs (blood pressure, pulse rate, and body temperature), 12lead ECG, and laboratory test results Persons who are 20 or older and 35 or younger Persons with a BMI 18.5 kg/m2 or more and 25.0 kg/m2 less Persons who are willing to participate in this trial before study initiation and who give their written consent in accordance with Good Clinical Practice Any finding of the medical examination (including BP, Pulse Rate (PR) and ECG) deviating from normal and of clinical relevance Any evidence of a clinically relevant concomitant disease Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders History of relevant orthostatic hypotension, fainting spells or blackouts Chronic or relevant acute infections History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) Intake of drugs with a long halflife (&gt;24 hours) within at least one month or less than 10 halflives of the respective drug prior to administration or during the trial Use of any drugs within 10 days prior to administration or during the trial Participation in another trial with an investigational drug within four months prior to administration or during the trial Smoker (&gt;10 cigarettes or &gt;3 cigars or &gt;3 pipes/day) Inability to refrain from smoking on trial days Alcohol abuse (more than 60 g/day) Drug abuse Blood donation (more than 100 mL) within four weeks prior to administration or during the trial Excessive physical activities (within one week prior to administration or during the trial) Any laboratory value outside the reference range that is of clinical relevance Inability to comply with dietary regimen of study centre 19. A history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) The use of concomitant medications that prolong the QT/QTc interval Any ECG value outside of the reference range and of clinical relevance including, but not limited to QRS interval &gt;120 ms Elevated urinary glucose levels at screening (&gt;15 mg/dl)</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>